What medications are contraindicated in patients with Chronic Kidney Disease (CKD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications Contraindicated or Requiring Caution in CKD Patients

Patients with CKD must avoid specific nephrotoxic medications entirely, while many commonly prescribed drugs require dose adjustment based on eGFR to prevent further kidney damage, drug accumulation, and life-threatening adverse effects.

Absolute Contraindications (Avoid Completely)

Antidiabetic Agents

  • Glyburide (first-generation sulfonylurea) is absolutely contraindicated in any degree of CKD due to accumulation of active metabolites causing severe, prolonged hypoglycemia 1, 2, 3
  • Chlorpropamide should be avoided entirely in CKD patients 4
  • Metformin must be discontinued when eGFR <30 mL/min/1.73 m² (CKD stages G4-G5) due to lactic acidosis risk 5, 6

Antibiotics

  • Aminoglycosides (gentamicin, tobramycin, amikacin, neomycin, streptomycin) are potentially nephrotoxic and should be avoided when possible, requiring close monitoring if absolutely necessary 7, 8
  • Tetracyclines should be avoided due to nephrotoxicity 9
  • Nitrofurantoin is contraindicated as it produces toxic metabolites causing peripheral neuritis 9, 4

Herbal and Over-the-Counter Products

  • All herbal remedies should not be used in people with CKD 5
  • Over-the-counter medicines and dietary/herbal supplements require medical or pharmacist review before use 10, 5

Imaging Contrast Agents

  • Gadolinium-containing contrast media should not be used when eGFR <15 mL/min/1.73 m² (CKD G5) due to nephrogenic systemic fibrosis risk 5
  • For eGFR <30 mL/min/1.73 m² (CKD G4-G5), only macrocyclic chelate preparations (American College of Radiology group II and III agents) should be used if gadolinium is absolutely necessary 10, 5

Medications Requiring Temporary Discontinuation

During Acute Illness or Surgery

The following medications must be temporarily discontinued in patients with eGFR <60 mL/min/1.73 m² (CKD G3a-G5) during serious intercurrent illness, surgery, or conditions increasing AKI risk 5:

  • ACE inhibitors and ARBs 11, 5
  • Aldosterone inhibitors and direct renin inhibitors 5
  • Diuretics 5
  • NSAIDs 5
  • Metformin 11, 5
  • Lithium 5
  • Digoxin 5, 12
  • SGLT2 inhibitors (during prolonged fasting, surgery, or critical illness due to ketosis risk) 1

Critical pitfall: Failure to restart these medications after the acute event can lead to unintentional harm—a clear restart plan must be communicated and documented 10, 11

Medications Requiring Dose Adjustment by eGFR

NSAIDs (Use with Extreme Caution)

  • All NSAIDs (including naproxen, diclofenac, ibuprofen, nimesulide) should be reviewed and limited, as they are the most commonly misprescribed nephrotoxic drugs in CKD 10, 13, 14, 4
  • NSAIDs were prescribed to 56.3% of CKD patients in one study, with 35.6% receiving them for >90 days despite being contraindicated 14
  • Monitor eGFR, electrolytes closely if NSAIDs cannot be avoided 7, 10

Antidiabetic Agents Requiring Adjustment

  • Metformin: Continue if eGFR ≥45 mL/min; review use at eGFR 30-44 mL/min; discontinue at eGFR <30 mL/min 5
  • Second-generation sulfonylureas (glipizide, glimepiride, gliclazide): Can be used with caution but require conservative initiation and close glucose monitoring due to hypoglycemia risk 1, 3
  • Acarbose: Relatively contraindicated in stage III/IV CKD 4

Cardiovascular Medications

  • Digoxin: Requires dose adjustment and therapeutic level monitoring due to narrow therapeutic window 5, 12
  • Simultaneous use of ACE inhibitor + ARB + renin inhibitor is potentially harmful and contraindicated 15

Antimicrobials Requiring Adjustment

  • Most renally cleared antibiotics require dose adjustment based on eGFR 7, 10
  • Vancomycin: Requires regular monitoring of eGFR, electrolytes, and drug levels 5

Other High-Risk Medications

  • Baclofen: Must be dose-adjusted in CKD 12
  • Lithium: Requires regular monitoring of GFR, electrolytes, and drug levels 5
  • Calcineurin inhibitors: Require regular monitoring of GFR, electrolytes, and drug levels 5

Monitoring Requirements for All CKD Patients on Medications

Patients with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity require monitoring of 7, 10:

  • eGFR and electrolytes (both outpatient and inpatient settings)
  • Therapeutic medication levels when indicated
  • More frequent monitoring during transitions of care 10, 11

For medications requiring precision in dosing (narrow therapeutic or toxic range), use equations combining creatinine and cystatin C, or measured GFR rather than eGFR alone 10, 11

Clinical Algorithm for Medication Management in CKD

  1. Identify CKD stage by calculating eGFR using validated equations 10, 11

  2. Perform comprehensive medication review at every visit and transition of care to assess adherence, continued indication, and drug interactions 10, 11

  3. Check each medication against eGFR-based dosing requirements using validated references 7, 10

  4. Avoid nephrotoxic combinations: Do not use potentially nephrotoxic drugs concurrently (e.g., NSAIDs + ACE inhibitors + diuretics) 7, 8

  5. Establish collaborative relationships with pharmacists to enhance drug stewardship and manage complex medication regimens 7, 10

  6. Educate patients about expected benefits and risks so they can identify and report adverse events 10, 11

Common Prescribing Pitfalls to Avoid

  • 46.6% of CKD stage III/IV patients are prescribed at least one relatively contraindicated drug, demonstrating widespread inappropriate prescribing 4
  • CKD diagnosis alone does not reduce nephrotoxic drug prescribing—active intervention is required 14
  • Polypharmacy is common as CKD patients are often seen by multiple specialists who do not coordinate treatments 7, 16
  • Non-GFR factors (extremes of body weight, non-steady state conditions) require additional consideration for drug dosing 10, 11
  • Teratogenicity must be reviewed when prescribing to patients of childbearing potential 7, 10

References

Guideline

Management of Type 2 Diabetes in Patients with eGFR 40

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Diabetes in Patients with CKD Stage 5

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Gliclazide in Patients with Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Medication Safety Principles and Practice in CKD.

Clinical journal of the American Society of Nephrology : CJASN, 2018

Related Questions

Which medications and supplements should be avoided in a patient with stage 3 chronic kidney disease?
Is vonoprazan (Potassium-Competitive Acid Blocker) safe in patients with Chronic Kidney Disease (CKD)?
Is Procloperazine (procloperazine) safe to use in patients with Chronic Kidney Disease (CKD)?
What is the recommended dose of simethicone (Sodamint) for a patient with Chronic Kidney Disease (CKD)?
Can Chymoral Forte (pancreatin) be used in patients with chronic kidney disease, and what dosing and monitoring are recommended?
Is stevia safe for use in children, particularly those under 12 years of age or with pre-existing medical conditions?
What is the significance of soft tissue prominence in the upper mediastinum on a chest X-ray (Chest X-ray) and how should it be further evaluated?
What is the significance of analyzing urea and creatinine levels in ascitic fluid for a patient with suspected liver disease and impaired renal function?
What is the management approach for an asymptomatic adult patient with subclinical hyperthyroidism, presenting with low Thyroid-Stimulating Hormone (TSH) levels but normal free Triiodothyronine (T3) and free Thyroxine (T4) levels, and no significant past medical history?
What does grade 2 diastolic dysfunction on an echocardiogram (echo) mean for a 65-year-old male with supraventricular tachycardia (SVT)?
What are the diagnostic and treatment criteria for catheter-associated urinary tract infection (CAUTI) in an elderly patient with a history of urinary tract infections (UTIs) and underlying medical conditions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.